Risk Factor Analyses for Immune Reconstitution Inflammatory Syndrome in a Randomized Study of Early vs. Deferred ART during an Opportunistic Infection by Grant, Philip M. et al.
 
Risk Factor Analyses for Immune Reconstitution Inflammatory
Syndrome in a Randomized Study of Early vs. Deferred ART during
an Opportunistic Infection
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Grant, Philip M., Lauren Komarow, Janet Andersen, Irini Sereti,
Savita Pahwa, Michael M. Lederman, Joseph Eron, et al. 2010.
Risk factor analyses for immune reconstitution inflammatory
syndrome in a randomized study of early vs. deferred ART during
an opportunistic infection. PLoS ONE 5(7): e11416.
Published Version doi:10.1371/journal.pone.0011416
Accessed February 19, 2015 1:33:36 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:4596643
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAARisk Factor Analyses for Immune Reconstitution
Inflammatory Syndrome in a Randomized Study of Early
vs. Deferred ART during an Opportunistic Infection
Philip M. Grant
1*, Lauren Komarow
2, Janet Andersen
2, Irini Sereti
3, Savita Pahwa
4, Michael M.
Lederman
5, Joseph Eron
6, Ian Sanne
7, William Powderly
8, Evelyn Hogg
9, Carol Suckow
10, Andrew
Zolopa
1
1Stanford University, Palo Alto, California, United States of America, 2Statistical and Data Analysis Center, Harvard School of Public Health, Boston, Massachusetts, United
States of America, 3National Institute for Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America, 4University of
Miami, Miami, Florida, United States of America, 5Case Western University, Cleveland, Ohio, United States of America, 6University of North Carolina, Chapel Hill, North
Carolina, United States of America, 7Wits Health Consortium, Helen Joseph Hospital, Johannesburg, South Africa, 8University College Dublin, Dublin, Ireland, 9Social and
Scientific Systems, Incorporated, Silver Spring, Maryland, United States of America, 10Frontier Science and Technology Research Foundation, Amherst, New York, United
States of America
Abstract
Background: Immune reconstitution inflammatory syndrome (IRIS) is reported widely in patients initiating antiretroviral
therapy (ART). However, few studies are prospective, and no study has evaluated the impact of the timing of ART when
allocated randomly during an acute opportunistic infection (OI).
Methodology/Principal Findings: A5164 randomized 282 subjects with AIDS-related OIs (tuberculosis excluded), to early or
deferred ART. IRIS was identified prospectively using pre-defined criteria. We evaluated associations between IRIS and
baseline variables in subjects with follow-up on ART using Wilcoxon and Fisher’s exact tests, logistic regression, and Cox
models with time-varying covariates. Twenty of 262 (7.6%) subjects developed IRIS after a median of 33 days on ART.
Subjects with fungal infections (other than pneumocystis) developed IRIS somewhat more frequently (OR=2.7; 95% CI: 1.02,
7.2; p-value=0.06 (using Fisher’s exact test)). In Cox models, lower baseline and higher on-treatment CD4+ T-cell counts and
percentage were associated with IRIS. Additionally, higher baseline and lower on-treatment HIV RNA levels were associated
with IRIS. Corticosteroids during OI management and the timing of ART were not associated with the development of IRIS.
Implications: In patients with advanced immunosuppression and non-tuberculous OIs, the presence of a fungal infection,
lower CD4+ T-cell counts and higher HIV RNA levels at baseline, and higher CD4+ T-cell counts and lower HIV RNA levels on
treatment are associated with IRIS. Early initiation of ART does not increase the incidence of IRIS, and concern about IRIS
should not prompt deferral of ART.
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Introduction
Potent combination antiretroviral therapy (ART) has dramat-
ically reduced morbidity and mortality associated with HIV
infection [1,2], but its use can be complicated by immune
reconstitution inflammatory syndrome (IRIS) [3]. Although no
uniform definition exists, the diagnosis of IRIS requires the
worsening of a recognized (‘‘paradoxical’’ IRIS) or unrecognized
(‘‘unmasking’’ IRIS) pre-existing infection in the setting of
improving immunologic function. The pathophysiology is not
well-defined, but the prevailing view is that IRIS reflects the
restoration of pathogen-specific immune response to microbial
antigens [4].
IRIS has been reported in 10–40% of patients initiating ART
[5,6,7,8]. In some reports, IRIS has resulted in increased
hospitalizations [6] but generally does not portend a poor long-
term prognosis [9]. Most studies of IRIS in patients initiating ART
with active opportunistic infections (OIs) have been retrospective
and focused on tuberculosis, cryptococcosis, and Mycobacterium
avium complex (MAC) infection [5,6]. Although there have been
two recent prospective cohort studies evaluating the risk factors for
cryptococcal IRIS in resource-limited settings [10,11], there are no
PLoS ONE | www.plosone.org 1 July 2010 | Volume 5 | Issue 7 | e11416IRIS risk factor analyses where the impact of the timing of ART
has been evaluated in a randomized clinical trial.
Previously reported risk factors for the development of IRIS
include low baseline CD4+ T-cell count, a robust immunologic
and virologic response to ART, and a short interval between
initiation of treatment for the OI and ART [5,6,12]. Here, we
report a risk factor analysis for IRIS during a randomized clinical
trial of early versus deferred ART in the setting of an acute OI
[13].
Results
Of the 282 subjects enrolled in the trial, 262 initiated ART, had
at least one subsequent study visit and were included in this
analysis. The median age was 38 years and 86% were men. Thirty
percent (78/262) of individuals were African American, 35% (91/
262) were Hispanic, and 7% (18/262) were from South Africa.
The median CD4+ T-cell count was 29 cells/mL [IQR 12, 55]
with a median plasma HIV RNA level of 5.0 log10 copies/ml
[IQR 4.8, 5.7]. Prior to ART initiation, 65% (171/262) of subjects
were diagnosed with PCP (100 confirmed and 71 presumptive
cases), 14% (37/262) with cryptococcosis, 14% (37/262) with
bacterial infections, 6% (16/262) with mycobacterial infections,
5% (14/262) with toxoplasmosis, and 4% (10/262) with
histoplasmosis. Fifty-three percent of subjects (138/262) were
diagnosed with more than one OI at baseline. Ninety-two percent
of subjects (241/262) were ART-naı ¨ve at study entry.
Twenty of 262 subjects (7.6%; 95% CI: 4.7%–11.5%) had a
confirmed IRIS diagnosis by a study chair (Table 1). Three cases
of potential IRIS did not meet study definition of IRIS after
review. Two potential cases of IRIS with dermatologic manifes-
tations were excluded as their presentations were not deemed
specific enough to meet the study definition for IRIS. The other
potential case was excluded when an alternative diagnosis became
more likely after the initial report was filed. Review of study
subjects who had received corticosteroids or NSAIDs did not
reveal additional cases of IRIS. IRIS was confirmed in 8% of
subjects (14/171) with PCP, 5% (2/37) with bacterial infections,
Table 1. Characteristics of IRIS subjects
1.
Gender,
age(yrs)
OIs prior to
ART initiation
IRIS
etiology IRIS symptoms
Days between
OI treatment and
ART initiation
Days
between
ART
initiation
and IRIS
diagnosis
Baseline CD4+
countRIRIS
CD4+ count
(cells/mL)
Baseline HIV
RNARIRIS
HIV RNA
(log10
copies/mL)
M, 45 CM, PCP CM
2 Headache 1 (CM), 10 (PCP) 62 10R80 4.7R2.6
M, 44 MAC, PCP MAC
2 Fever, lymphadenopathy 6 (MAC), 43 (PCP) 26 62R759
4 5.5R3.4
M, 34 PCP Cryptococcus
3 Headache, submandibular mass 7 117 1R66 4.7R1.9
F, 47 PCP TB
3 Fever, cough, pleuritic chest pain 8 34 64R102 5.0R3.9
M, 40 PCP PCP
2 Fever, cough, dyspnea 9 82 25R186 6.1R3.0
M, 45 PCP, Candida
esophagitis
VZV
3 Vesicular rash 9 138 5R153 6.0R2.0
M, 30 PCP CMV
3 Eye redness, visual loss 11 43 17R144 5.7R2.7
M, 42 PCP, PNA PCP
2 Fever, cough, dyspnea 11 22 18R47 4.7R2.7
M, 38 Histoplasmosis HCV
3 Nausea, vomiting, hepatitis 14 229 3R37 6.1R6.0
5
M, 31 MAC, CM, PNA MAC
2 Fever 23 (MAC), 48 (CM) 31 44R74 5.7R2.9
M, 39 CM CM
2 Fever, headache 29 26 29R80 4.7R2.5
M, 42 CM CM
2 Headache, nuchal rigidity, photophobia 37 116 31R128 4.8R2.2
M, 37 PCP PCP
2 Fever, cough 42 35 76R481 6.3R3.6
M, 27 PCP, Candida
esophagitis
MAC
3 Fever, night sweats, diarrhea 44 15 52R43 6.3R5.7
M, 42 PCP, KS MAC
3 Fever, night sweats, lymphadenopathy 45 50 14R231 5.7R2.4
F, 35 PCP MAC
3 Fever, night sweats 46 28 17R464 6.0R2.1
M, 45 Histoplasmosis,
Cryptosporidia
Histoplasmosis
2 Fever 47 (Histoplasma), 42
(Cryptosporidia)
18 21R190
4 4.9R3.2
M, 24 CM CM
2 Blurry vision (due to papilledema) 48 29 14R44 4.7R2.3
M, 45 PCP PCP
2 Fever, chills, dyspnea 49 13 22R101
4 4.6R1.9
M, 36 PCP MAC
3 Fever, lymphadenopathy 54 29 40R357 5.4R2.6
1IRIS=immune reconstitution inflammatory syndrome; OI=opportunistic infection; ART=combination antiretroviral therapy; M=male; F=female; CM=cryptococcal
meningitis; PCP=Pneumocystis jirovecii pneumonia; PNA=bacterial pneumonia; MAC=Mycobacterium avium complex; TB=tuberculosis; VZV=varicella-zoster virus;
CMV=cytomegalovirus; HCV=hepatitis C virus; KS=Kaposi’s sarcoma.
2=Paradoxical IRIS.
3=Unmasking IRIS.
4IRIS CD4+ T-cell counts listed in table, in general, are from at/or before time of IRIS diagnosis; however, these values are from after time of IRIS but all within 3 days of
time of IRIS).
5=at the time of IRIS diagnosis (based on liver biopsy findings), ART had been discontinued; previously subject had robust response to ART with HIV RNA levels below
limit of quantification.
doi:10.1371/journal.pone.0011416.t001
IRIS Risk Factor Analysis
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cryptococcosis and 20% of subjects with histoplasmosis), and 13%
of subjects (2/16) with mycobacterial infections.
The median time to IRIS diagnosis after ART initiation was 33
days [IQR 26, 72] and was not significantly different between
those assigned to early and deferred ART (72 vs. 29 days,
respectively; p=0.25). At the time of IRIS diagnosis, the median
change in CD4+ T cells was an increase of 88 cells/mL [IQR 36,
193] and the median decrease in HIV RNA levels was 2.7 log10
copies/mL [IQR 2.0, 2.9]. Eleven subjects had paradoxical IRIS
and 9 subjects had unmasking IRIS. The median time to IRIS
diagnosis after ART initiation and the median change in CD4+ T
cells and HIV RNA levels at the time of IRIS were similar
between those subjects who developed paradoxical and unmasking
IRIS (data not shown). Six subjects had IRIS reactions to MAC, 5
to cryptococcus, 4 to Pneumocystis jirovecii, and 1 each to
Mycobacterium tuberculosis, varicella-zoster virus, cytolomegalovirus,
hepatitis C virus, and Histoplasma capsulatum. The presentations of
IRIS are described in Table 1.
Eighteen of twenty subjects continued ART after the diagnosis
of IRIS. Corticosteroids were used in the treatment of 35% (7/20)
of IRIS cases for a median of 83 days and for 3 of the 5 cases of
cryptococcal IRIS. The majority of IRIS cases resolved quickly
and without sequelae. However, the four most protracted cases
(one in the early ART treatment arm and three in the deferred
ART arm) were due to cryptococcus. Symptoms persisted to weeks
24, 27, 31, and 46 of ART before finally resolving. However, the
48 week study outcomes of these cases were favorable with no
additional OIs occurring, and all surviving to study completion.
Only one of the 20 subjects with IRIS died (comparable to the
8.5% mortality in the entire ACTG A5164 study population), and
this death was not due to IRIS, as determined by the local
investigator and confirmed by the study chairs.
In univariate analyses, no baseline variables, other than entry
OI, were significantly associated with the development of IRIS
(Table 2). Importantly, subjects assigned to early ART were no
more likely to develop IRIS than those assigned to deferred ART
(OR=0.60; 95% CI: 0.24, 1.5; p=0.35). Subjects with non-PCP
fungal infections developed IRIS somewhat more frequently
(OR=2.7; 95% CI: 1.02, 7.2; p=0.06 (Fisher’s exact test);
p=0.045 (non-exact test)). Lower baseline CD4+ T-cell count or
percentage were not associated with the development of IRIS, nor
were markers of OI disease severity such as hospitalization at study
entry or elevated LDH. The use of corticosteroids during the
management of the acute OI was not associated with a significant
reduction in the frequency of IRIS (OR=0.57; 95% CI: 0.23, 1.4;
p=0.24), although no subjects developed IRIS while still on
corticosteroids.
Most subjects in the study population had a robust response to
ART. The median 4-week change in CD4+ T-cell count and
plasma HIV RNA level was +71 cells/mL [IQR 30, 141] and
22.10 log10 copies/mL [IQR 22.60, 21.55]. Table 3 groups
subjects into 3 groups those who developed IRIS by week 4
(n=10), those who developed IRIS after week 4 (n=10), and
subjects who never developed IRIS (n=242). At week 4 of ART,
subjects already diagnosed with IRIS had a median CD4+ T-cell
count of 171 cells/mL (IQR 74, 357), while subjects who would
later have IRIS diagnosed had a median CD4+ T-cell count of 91
cells/mL (IQR 75, 144) and subjects who never had IRIS had a
median CD4+ T-cell count of 116 cells/mL (IQR 56, 192).
Subjects who developed IRIS by 4 weeks also had a higher median
CD4+ percentage (13.0 [IQR 7.0, 18.0] vs. IRIS post-week 4: 8.5
[IQR 7.0, 12.0] vs. No IRIS: 8.0 [5.0, 13.0]) and lower median
log10 HIV RNA levels (2.6 [IQR 2.4, 2.9] vs. IRIS post-week 4:
3.2 [IQR 2.5, 3.6] vs. No IRIS: 3.1 [IQR 2.6, 3.6]). Grouping the
subjects into those who developed IRIS by week 8 (n=14), those
who developed IRIS after week 8 (n=6), and subjects who never
developed IRIS (n=242) showed a similar pattern with subjects
who developed IRIS before this time period showing a more
robust immunologic and virologic response compared to those
who developed IRIS subsequently and those who never developed
IRIS (data not shown).
In multivariate Cox models using time-varying covariates, lower
baseline CD4+ T-cell count (HR=0.79 per 10 additional CD4+
cells/mL; 95% CI: 0.65, 0.97; p=0.022), higher CD4+ T-cell
counts on ART (HR=1.08 per additional 10 CD4+ cells/mL;
95% CI: 1.03, 1.13; p=0.002), and the presence of a baseline non-
PCP fungal infection (HR=3.01; 95% CI: 1.16, 7.80; p=0.023)
were significantly associated with the development of IRIS
(Table 4). Lower baseline CD4+ percentage (HR=0.17 per
additional 10 increase in CD4%; 95% CI: 0.04, 0.69; p,0.001),
higher CD4+ percentage on ART (HR=3.90 per additional 10
increase in CD4%; 95% CI: 1.79, 8.47; p=0.012) and baseline
non-PCP fungal infection (HR=3.08; 95% CI:1.20, 7.89;
p=0.019) were also significantly associated with IRIS.
Cox models evaluating change in CD4+ T-cells and CD4+
percentage (rather than the absolute values on ART) versus the
risk of IRIS produced similar results. Low baseline CD4+ T-cell
count (HR=0.83 per additional 10 CD4+ cells/mL; 95% CI: 0.70,
1.00; p=0.044), change in CD4+ T-cell count (HR=1.08 per
additional 10 CD4+ cells/mL; 95% CI: 1.03, 1.13; p=0.002), and
non-PCP fungal infection (HR=3.03; 95% CI: 1.17, 7.84;
p=0.022) were significantly associated with the development of
IRIS. Larger change in CD4+ percentage (HR=3.52 per
additional 10 increase in CD4%; 95% CI: 1.50, 8.27 ;
p=0.004) and non-PCP fungal infections (HR=2.87; 95% CI
1.13, 7.29; p=0.026) were both significantly associated with the
development of IRIS, while low baseline CD4+ percentage did not
reach significance in this model (HR=0.36 per additional 10
increase in CD4%; 95% CI: 0.11, 1.16; p=0.086).
In multivariate Cox models, baseline HIV RNA levels
(HR=2.49 per 1 log increase in HIV RNA; 95% CI:1.19, 5.21;
p=0.015), HIV RNA levels on ART (HR=0.43 per 1 log
increase in HIV RNA; 95% CI:0.24, 0.78; p=0.006), and non-
PCP fungal infections (HR=3.03; 95% CI:1.20, 7.64; p=0.019)
also predicted the development of IRIS. There was no relationship
between CD8+ T-cell counts and IRIS.
Discussion
In this prospective study of risk factors associated with IRIS
during a randomized clinical trial, the incidence of IRIS was 7.6%
(95% CI: 4.7%–11.5%) over 48 weeks among those with follow-up
on ART. Our estimate is in line with a prospective study in
asymptomatic patients from South Africa starting ART which
reported a rate of 10.4% [8]. Prospective studies of IRIS in
patients with cryptococcal disease in South Africa and Thailand
showed incidences of 17% and 13%, respectively [10,11], which is
in the same range as the 14% of subjects who developed IRIS with
cryptococcal infections in our study. Our risk estimate of IRIS for
subjects initiating ART with non-tuberculous mycobacterial
disease is 13%. Importantly, these estimates are substantially
lower than those from retrospective studies. For instance, in a
retrospective study among patients initiating ART after tubercu-
losis, MAC or cryptococcal infections, 32% of patients developed
IRIS [6]. Even in asymptomatic patients initiating ART,
retrospective studies frequently report rates of IRIS in excess of
20% [7,14].
IRIS Risk Factor Analysis
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reflect differences in case definitions of IRIS, the effect of active
case finding using retrospective data (case finding bias), lack of
uniform diagnostic testing at suspected IRIS, and different study
populations. While some cases of IRIS are straightforward (e.g.,
MAC lymphadenitis in a patient with immune recovery), other
cases are less definitive (e.g., the development of genital herpes in a
patient responding to ART). As this study was prospective, our
results are more reflective of how the diagnosis of IRIS is made in
practice. Less prevalent in this series are IRIS cases with primarily
dermatologic manifestations which constitute the majority of cases
in some retrospective studies [7,12]. These can be difficult to
distinguish from coincidental instances of dermatologic disease
that are common in patients with advanced immune deficiency
[15]. Validated and widely accepted disease-specific definitions of
IRIS would help standardize reporting of IRIS. Efforts have been
made to standardize definitions for TB IRIS and cryptococcal
IRIS in recent years [16], and these efforts should be extended to
standardize case definitions of IRIS for other OIs as well.
Initiation of ART closer to the diagnosis of the OI has been
associated with the development of IRIS in at least two
retrospective studies [6,17]. Treatment guidelines cite the risk of
IRIS as a potential downside to initiation of ART early during the
treatment of an OI [18,19]. However, in our study, subjects
randomized to early ART were not more likely to develop IRIS;
6.3% of the subjects treated early experienced IRIS, compared to
10.4% of subjects who received deferred ART. Similar results
were found in two prospective studies of cryptococcal IRIS, where
Table 2. Univariate Analyses of Predictors for IRIS.
Characteristic Subjects with IRIS Subjects without IRIS Odds Ratio (95% CI) P-value
1
Total 20 242
Median Age (IQR) 40 (35, 45) 38 (33, 44) N.A. 0.91
Ethnicity
Black 5 (25%) 73(30%) Ref 0.58
Hispanic 10 (50%) 81 (33%) 1.80 (0.59–5.52)
Other 4 (20%) 71 (29%) 0.82 (0.21–3.19)
South Africa 1 (5%) 17 (7%) 0.86 (0.09–7.84)
Treatment Arm
Early 8 (40%) 127 (52%) 0.60 (0.24–1.53) 0.35
Deferred 12 (60%) 115 (48%)
ART prior to entry
Naı ¨ve 18 (90%) 223 (92%) 0.77 (0.17–3.55) 0.67
Experienced 2 (10%) 19 (8%)
ART Regimen
PI-based 17 (85%) 210 (87%) 0.86 (0.24–3.11) 0.74
Non-PI-based 3 (15%) 32 (13%)
Hospitalized at ART Start
Yes 4 (20%) 33 (14%) 1.58 (0.50–5.03) 0.21
No 16 (80%) 209 (86%)
Steroids during Acute OI
Yes 9 (45%) 141 (58%) 0.59 (0.23–1.47) 0.35
No 11 (55%) 101 (42%)
Pre-ART OIs
2
PCP 14 (70%) 157 (65%) 1.26 (0.47–3.41) 0.81
Bacterial Infection 2 (10%) 35 (14%) 0.66 (0.15–2.96) 0.75
Mycobacterial Infection 2 (10%) 14 (6%) 1.81 (0.38–8.59) 0.35
Non-PCP Fungal Infection 7 (35%) 40 (17%) 2.72 (1.02–7.24) 0.06
3
Toxoplasmosis 0 (0%) 14 (6%) N.A.
4 0.61
Median Baseline CD4+ (cells/mL) (IQR) 22 (14, 42) 31 (12, 56) N.A. 0.30
Median Baseline CD4+% (IQR) 3.5 (1, 7) 4 (2, 7) N.A. 0.66
Median Baseline CD8+ (cells/mL) (IQR) 472 (217, 793) 446 (270, 719) N.A. 0.97
Median Baseline Viral Load (log10 copies/mL) (IQR) 5.5 (4.8, 6.0) 5.0 (4.8, 5.7) N.A. 0.28
1P-values by Fisher’s exact test for dichotomous variables and Wilcoxon Rank Sum Test for continuous variables.
2Participants could have mulitiple opportunistic infections (OIs) so percents do not sum to 1.
3At margin of significance; P-value is 0.045 using non-exact test.
4Not calculated due to cell containing 0.
N.A.=Not applicable.
doi:10.1371/journal.pone.0011416.t002
IRIS Risk Factor Analysis
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[10,11].
A small randomized study conducted in Zimbabwe recently
showed increased mortality with early ART in cryptococcal
meningitis [20]. In this study, early ART was initiated within
72 hours of cryptococcal diagnosis. IRIS events were not
evaluated, but the authors speculate that the increased mortality
with early ART may have been due to increased rates of IRIS. If
this is true, the increased rates of IRIS could have been due to
ART being initiated very early (e.g., within 72 hours), as opposed
to ART initiated a median of 12 days after the start of OI
treatment, as in our study. The use of the more slowly fungicidal
drug, fluconazole, in the Zimbabwe study, as opposed to
amphotericin B in our study and others, could also account for
the reported differences in the relationship between the timing of
ART and IRIS in cryptococcal meningitis.
Furthermore, in the retrospective studies, residual confounding
possibly related to unmeasured clinical factors or differences in
adherence patterns could explain the association of earlier ART to
IRIS [6,17]. Indeed, in the Shelburne study, patients who
developed IRIS appear to have been substantially more adherent
to ART than their counterparts as evidenced by significantly
higher rates of virologic suppression to ,400 copies/mL at 24
months (78% vs. 36%; p,0.0001) [6]. If adherent patients were
more likely to start treatment earlier (due to fewer social obstacles,
greater motivation, more regular clinic attendance, etc.), this
might account for the apparent relationship between earlier
treatment initiation after acute OI presentation and the develop-
ment of IRIS.
The receipt of corticosteroids during the management of the
acute OI was not significantly associated with a reduction in the
overall risk of IRIS, although a clinically meaningful reduction can
not be excluded due to the relatively few patients who developed
IRIS in this study. However, no patients developed IRIS while still
on corticosteroids – thereby if not preventing at least possibly
delaying the onset of IRIS. It is possible that a longer course of
corticosteroids or other immune modulating agents could not only
delay IRIS but actually reduce the risk of IRIS, but the risk/
benefit of these types of approaches to IRIS would require
systematic study. Also, it is possible that the lack of association
between the receipt of corticosteroids and IRIS was due to
confounding by indication, as IRIS has been associated with
severity of underlying OI in some studies [5,17], and subjects with
more severe illness at baseline may have been more likely to have
received corticosteroids.
In this study, in univariate analyses, baseline clinical features,
other than the presenting OI (non-PCP fungal infections), did not
distinguish subgroups at higher risk for IRIS. We did not find any
significant differences in baseline characteristics between subjects
who developed IRIS and those who did not, although the
Table 3. T-cell subsets and HIV RNA Levels versus IRIS.
Change from
Baseline IRIS Baseline Week 4
n Median (IQR) n Median (IQR)
CD4+ (cells/mL)
#Wk 4 10 26 (18, 44) 10 171 (74, 357)
.Wk 4 10 16 (5, 31) 10 91 (75, 144)
No IRIS 242 31 (12, 56) 225 116 (56, 192)
CD4+%
#Wk 4 10 5.5 (2.0, 7.0) 10 13.0 (7.0, 18.0)
.Wk 4 10 3.0 (1.0, 6.0) 10 8.5 (7.0, 12.0)
No IRIS 239 4.0 (2.0, 7.0) 225 8.0 (5.0, 13.0)
CD8+ (cells/mL)
#Wk 4 10 362 (198, 585) 10 692 (507, 1772)
.Wk 4 10 697 (269, 823) 10 613 (477, 1273)
No IRIS 238 446 (270, 719) 225 770 (488, 1183)
CD8+%
#Wk 4 10 54 (45, 63) 10 56 (44, 65)
.Wk 4 10 70 (58, 74) 10 61 (53, 68)
No IRIS 238 62 (49, 73) 225 62 (52, 70)
log10 viral load
#Wk 4 10 5.2 (4.7, 5.7) 10 2.6 (2.4, 2.9)
.Wk 4 10 5.7 (4.8, 6.1) 10 3.2 (2.5, 3.6)
No IRIS 242 5.0 (4.7, 5.7) 229 3.1 (2.6, 3.6)
1 IRIS=immune reconstitution inflammatory syndrome; 2 ART=combination
antiretroviral therapy.
doi:10.1371/journal.pone.0011416.t003
Table 4. Cox Proportional Hazards Models Using Time Varying Covariate Models.
ART start value Covariate on ART Non-PCP Fungal Infection
CD4+ (cells/mL) Hazard Ratio (per additional 10 cells) 0.79 1.08 3.01
95% Confidence Interval 0.65, 0.97 1.03, 1.13 1.16, 7.80
P-value 0.022 0.002 0.023
CD4+% Hazard Ratio (per additional 10%) 0.17 3.90 3.08
95% Confidence Interval 0.04, 0.69 1.79, 8.47 1.20, 7.89
P-value ,0.001 0.012 0.019
CD8+ (cells/mL) Hazard Ratio (per additional 100 cells) 0.99 1.03 2.76
95% Confidence Interval 0.93, 1.05 0.99, 1.07 1.09, 6.99
P-value 0.66 0.21 0.032
log10 viral load Hazard Ratio (per 1 log10 increase) 2.49 0.43 3.03
95% Confidence Interval 1.19, 5.21 0.24, 0.78 1.20, 7.64
P-value 0.015 0.006 0.019
doi:10.1371/journal.pone.0011416.t004
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study may have limited our ability to detect differences.
However, in multivariate time-varying Cox models, after
controlling for immune and virologic parameters over time and
non-PCP fungal infections, baseline CD4+ T-cell count, CD4+
percentage, and HIV RNA levels were predictors of IRIS,
consistent with previous research [7,12,21]. The apparent
incongruity between the findings in the univariate and Cox
analyses regarding the importance of these parameters in the
prediction of IRIS implies complex relationships between baseline
immunologic and virologic values, these parameters over time,
and the development of IRIS (e.g., those with lower baseline
CD4+ T-cell counts or higher HIV RNA levels were both more
likely to have a more robust response to ART and to develop
IRIS). Perhaps, because of relatively uniform low pre-ART CD4+
T-cell counts and high HIV RNA levels, the significance of
baseline values only emerges in models that jointly consider
baseline and values over time. Like others, we found higher CD4+
T-cell counts and CD4+ percentages and lower HIV RNA levels
on treatment to be associated with the development of IRIS
[5,10,21].
Patients with known TB were excluded from the trial, and it is
unknown whether these results would be applicable to
individuals presenting with TB. Furthermore, ACTG A5164
enrolled predominantly subjects with PCP, and corticosteroids
were used frequently during the study. There is limited power to
generalize the conclusions of this study to less common OIs and
to patients who are not given corticosteroids during the
management of their acute OI. However, ACTG A5164 is the
largest trial to date which has reported the effects of the timing
of ART during an acute OI on the rates of IRIS, and there was
no trend towards increased IRIS with early ART for any entry
OI or in subjects who did not receive corticosteroids for their
a c u t eO I .D u et ot h em u l t i p l ec o mparisons involved in this
study, marginally significant associations should be interpreted
cautiously. Also, case reviewers were limited by what was
prospectively recorded by the site. Data on severity of the
presenting OI were not uniformly available while information
on symptoms of IRIS, medications, and laboratory data were
more complete.
In conclusion, retrospective reports appear to have overesti-
mated the occurrence of IRIS after ART initiation in advanced
HIV disease. The presence of low baseline CD4+ T-cell count and
high HIV RNA levels, a non-PCP fungal infection, and improved
immunologic and virologic response to ART predict the
development of IRIS. Corticosteroids, as used in this study, may
delay the onset of IRIS but were not associated with a reduction in
its frequency. In subjects with non-TB OIs, early initiation of ART
does not increase the incidence of IRIS, and concern about IRIS
should not be a reason to defer ART.
Methods
The protocol for the primary study and supporting CONSORT
checklist are available as supporting information; see Checklist S1
and Protocol S1.
Ethics Statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The protocol was approved by all
46 of the participating sites’ Institutional Review Boards, including
the Stanford University Institutional Review Board, the lead site
for the study. Written informed consent was obtained from
subjects prior to entry.
AIDS Clinical Trials Group (ACTG) A5164 was a randomized
trial of early versus deferred ART in subjects with an acute AIDS-
defining OI or a serious bacterial infection (defined as bacterial
pneumonia or other bacterial infection of a deep tissue, body
cavity, or other normally sterile site and a CD4+ T-cell
count,200 cells/mL). Allowable entry OIs included Pneumocystis
jirovecii pneumonia (PCP), other fungal infections (including those
due to cryptococcus or histoplasma), toxoplasmosis, cytomegalo-
virus infection, and non-tuberculous mycobacterial infection.
Patients with tuberculosis (TB) were excluded from the study but
were allowed to stay on-study if the diagnosis was made after
randomization. Subjects were only allowed to have minimal ART
exposure prior to study entry (no ART within 8 weeks prior to
study entry, no more than 31 days of any ART within 6 months
prior to study entry, and no more than one ART regimen on
which they had experienced treatment failure). Subjects were
enrolled from the United States, including Puerto Rico, and South
Africa. Subjects were randomized within 14 days of starting
therapy for the OI (or bacterial infection) that determined study
eligibility. Subjects were randomized 1:1 to receive ART
immediately after study entry or to have ART deferred for at
least 4 weeks after randomization. The study provided lopinavir/
ritonavir, stavudine, and, starting in September 2005, tenofovir/
emtricitabine, but clinicians could select any standard, recom-
mended ART regimen.
Subjects were followed prospectively with study visits at weeks 4,
8, 12, 16, 24, 32, 40, and 48, and at time of suspected IRIS, if
outside the scheduled visit window. Measurement of CD4+ and
CD8+ T cells and plasma HIV RNA levels were performed at
study entry, at initiation of ART, at weeks 4, 8, 12, 16, 24, 32, and
40 following initiation of ART, at time of suspected IRIS, and at
study completion. Further details of the trial have been reported
elsewhere [13].
IRIS was pre-defined in the protocol as symptoms consistent
with an infectious/inflammatory condition, temporally related to
the initiation of ART and associated with an increase in CD4+ T-
cell count and/or a decrease in plasma HIV-1 RNA levels, but not
explained by a newly acquired infection, the expected clinical
course of a previously diagnosed infection, or the side effects of
ART. When IRIS was diagnosed by a site investigator, case
records were reviewed by a study chair (W.P. or A.Z.) or an
independent reviewer (all blinded to study arm assignment) for
confirmation. To confirm that sites had not under-reported IRIS,
an independent reviewer retrospectively evaluated study records of
all subjects who were prescribed corticosteroids or non-steroidal
anti-inflammatory drugs (NSAIDs) during the study in an attempt
to uncover additional cases of IRIS. Details of the clinical
presentation, management, and outcome of IRIS were extracted
from study records by two investigators (P.G. and A.Z.) using a
standardized abstraction tool.
As the study definition of IRIS is only applicable to subjects who
started ART, this analysis is limited to subjects who initiated ART
and had at least one subsequent study visit with baseline defined as
the time of ART initiation. Comparisons between subjects with
and without an IRIS diagnosis were evaluated using the Wilcoxon
rank-sum test for continuous and ordered categorical variables and
Fisher’s exact test for categorical variables. P-values,0.05 were
considered statistically significant. In this secondary analysis,
results were not adjusted for multiple comparisons. Logistic
regression was used to investigate the association between baseline
characteristics, laboratory values and entry OIs with the odds
of having an IRIS diagnosis. Cox models with time-varying
covariates were used to evaluate the association between IRIS
diagnosis and CD4+ and CD8+ T-cell counts, CD4+ and CD8+
IRIS Risk Factor Analysis
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varying covariates used a last value carried forward approach until
the time a new measurement was obtained.
Supporting Information
Checklist S1 CONSORT Checklist
Found at: doi:10.1371/journal.pone.0011416.s001 (0.06 MB
DOC)
Protocol S1 Trial Protocol
Found at: doi:10.1371/journal.pone.0011416.s002 (0.58 MB
DOC)
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